JP2008534552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534552A5 JP2008534552A5 JP2008503489A JP2008503489A JP2008534552A5 JP 2008534552 A5 JP2008534552 A5 JP 2008534552A5 JP 2008503489 A JP2008503489 A JP 2008503489A JP 2008503489 A JP2008503489 A JP 2008503489A JP 2008534552 A5 JP2008534552 A5 JP 2008534552A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patients
- active ingredient
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 239000004480 active ingredient Substances 0.000 claims 12
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims 8
- 208000007536 Thrombosis Diseases 0.000 claims 8
- 206010047249 Venous thrombosis Diseases 0.000 claims 8
- 239000003868 thrombin inhibitor Substances 0.000 claims 8
- 229940127218 antiplatelet drug Drugs 0.000 claims 7
- 229940125782 compound 2 Drugs 0.000 claims 7
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000007887 coronary angioplasty Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000010125 myocardial infarction Diseases 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical group C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 4
- 108010014173 Factor X Proteins 0.000 claims 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 4
- 229960003009 clopidogrel Drugs 0.000 claims 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000003055 low molecular weight heparin Substances 0.000 claims 4
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 4
- 230000009861 stroke prevention Effects 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 230000002537 thrombolytic effect Effects 0.000 claims 4
- -1 2-{[4- (Hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazol-5-carbonyl Chemical group 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003698 antivitamin K Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000000399 orthopedic effect Effects 0.000 claims 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 229940019333 vitamin k antagonists Drugs 0.000 claims 2
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
- 229920001499 Heparinoid Polymers 0.000 claims 1
- 102000007625 Hirudins Human genes 0.000 claims 1
- 108010007267 Hirudins Proteins 0.000 claims 1
- 229960003856 argatroban Drugs 0.000 claims 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims 1
- 229960003850 dabigatran Drugs 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical group CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000002628 heparin derivative Substances 0.000 claims 1
- 239000002554 heparinoid Substances 0.000 claims 1
- 229940025770 heparinoids Drugs 0.000 claims 1
- 229940006607 hirudin Drugs 0.000 claims 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229950003291 inogatran Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002137 melagatran Drugs 0.000 claims 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960005001 ticlopidine Drugs 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006711 | 2005-03-29 | ||
| PCT/EP2006/061046 WO2006103206A2 (en) | 2005-03-29 | 2006-03-27 | Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534552A JP2008534552A (ja) | 2008-08-28 |
| JP2008534552A5 true JP2008534552A5 (https=) | 2009-05-21 |
Family
ID=36423564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503489A Pending JP2008534552A (ja) | 2005-03-29 | 2006-03-27 | 血栓症治療用の新規な医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060222640A1 (https=) |
| EP (1) | EP1885354A2 (https=) |
| JP (1) | JP2008534552A (https=) |
| KR (1) | KR20070116936A (https=) |
| CN (1) | CN101151030A (https=) |
| AR (1) | AR056291A1 (https=) |
| AU (1) | AU2006228600A1 (https=) |
| BR (1) | BRPI0608656A2 (https=) |
| CA (1) | CA2602563A1 (https=) |
| CL (1) | CL2010000395A1 (https=) |
| EA (1) | EA015122B1 (https=) |
| IL (1) | IL186267A0 (https=) |
| MX (1) | MX2007010664A (https=) |
| NO (1) | NO20074149L (https=) |
| NZ (1) | NZ562775A (https=) |
| TW (1) | TW200722089A (https=) |
| UA (1) | UA92603C2 (https=) |
| WO (1) | WO2006103206A2 (https=) |
| ZA (1) | ZA200706698B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906894B1 (en) | 2000-07-27 | 2014-12-09 | Thomas N. Thomas | Methods for preventing and treating thrombotic disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| IL159273A0 (en) * | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| US20080274166A1 (en) * | 2005-06-10 | 2008-11-06 | Transpharma Medical Ltd. | Patch for Transdermal Drug Delivery |
| AR062057A1 (es) * | 2006-07-17 | 2008-10-15 | Boehringer Ingelheim Int | Uso de los inhibidores directos de la trombina |
| WO2008043759A1 (en) * | 2006-10-10 | 2008-04-17 | Boehringer Ingelheim International Gmbh | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| DE102006051625A1 (de) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| CA2704164A1 (en) * | 2007-10-29 | 2009-05-07 | Transpharma Medical Ltd. | Vertical patch drying |
| WO2010013231A2 (en) * | 2008-07-29 | 2010-02-04 | Yeda Research And Development Co. Ltd. | Modulation of coagulation factors and effectors of same for control of transplant organ size |
| WO2010029552A1 (en) * | 2008-09-10 | 2010-03-18 | Transpharma Medical Ltd. | Transdermal delivery of oligosaccharides |
| JP2013510072A (ja) | 2008-11-11 | 2013-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法 |
| CN102209546A (zh) * | 2008-11-11 | 2011-10-05 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法 |
| AR074108A1 (es) * | 2008-11-11 | 2010-12-22 | Boehringer Ingelheim Int | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina |
| RU2011132125A (ru) | 2008-12-30 | 2013-02-10 | Тромбологик Апс | Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения |
| JP6012629B2 (ja) * | 2011-01-25 | 2016-10-25 | ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ | 細胞移植のための組成物および方法 |
| CN102250099B (zh) * | 2011-05-16 | 2013-10-16 | 中国药科大学 | 一类非肽类抗凝血酶抑制剂、其制法以及医药用途 |
| EP2806879B1 (en) | 2012-01-25 | 2019-03-06 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| EP2722033A1 (en) * | 2012-10-19 | 2014-04-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical Compositions of Dabigatran Free Base |
| EP2722034B1 (en) * | 2012-10-19 | 2020-09-16 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
| ES2759228T3 (es) | 2013-07-05 | 2020-05-08 | Univ Catholique Louvain | Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado |
| DE102014108210A1 (de) * | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105250286A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种抗血栓组合物 |
| CN108236612A (zh) * | 2016-12-27 | 2018-07-03 | 李志忠 | 用于冠脉介入手术中抗凝的组合产品及其用途 |
| US12251377B2 (en) | 2019-03-06 | 2025-03-18 | University Of Rochester | Anticoagulant compositions and uses thereof |
| US11654036B2 (en) | 2020-05-26 | 2023-05-23 | Elixir Medical Corporation | Anticoagulant compounds and methods and devices for their use |
| CN115192691B (zh) * | 2022-08-31 | 2025-03-04 | 晓恩医药包装材料(安庆)有限公司 | 一种阿加曲班注射液及预灌封注射器 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| NZ286082A (en) * | 1995-03-15 | 1998-09-24 | Behringwerke Ag | Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment |
| FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
| DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB9930540D0 (en) * | 1999-12-23 | 2000-02-16 | Rhone Poulenc Rorer Pharma | Chemical compounds |
| GB0014134D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| KR20040044514A (ko) * | 2001-09-14 | 2004-05-28 | 미쯔비시 웰 파마 가부시키가이샤 | 항혈전약과 피라졸론 유도체의 조합 약제 |
| KR101005716B1 (ko) * | 2002-03-07 | 2011-01-05 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태 |
| DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2004231306A1 (en) * | 2003-04-24 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
-
2006
- 2006-03-26 US US11/277,503 patent/US20060222640A1/en not_active Abandoned
- 2006-03-27 MX MX2007010664A patent/MX2007010664A/es not_active Application Discontinuation
- 2006-03-27 EP EP06725316A patent/EP1885354A2/en not_active Withdrawn
- 2006-03-27 UA UAA200711762A patent/UA92603C2/ru unknown
- 2006-03-27 KR KR1020077024953A patent/KR20070116936A/ko not_active Ceased
- 2006-03-27 WO PCT/EP2006/061046 patent/WO2006103206A2/en not_active Ceased
- 2006-03-27 JP JP2008503489A patent/JP2008534552A/ja active Pending
- 2006-03-27 NZ NZ562775A patent/NZ562775A/en unknown
- 2006-03-27 AU AU2006228600A patent/AU2006228600A1/en not_active Abandoned
- 2006-03-27 CN CNA2006800108359A patent/CN101151030A/zh active Pending
- 2006-03-27 EA EA200701841A patent/EA015122B1/ru not_active IP Right Cessation
- 2006-03-27 CA CA002602563A patent/CA2602563A1/en not_active Abandoned
- 2006-03-27 BR BRPI0608656-0A patent/BRPI0608656A2/pt not_active IP Right Cessation
- 2006-03-28 TW TW095110732A patent/TW200722089A/zh unknown
- 2006-03-29 AR ARP060101205A patent/AR056291A1/es unknown
-
2007
- 2007-08-10 NO NO20074149A patent/NO20074149L/no not_active Application Discontinuation
- 2007-08-13 ZA ZA200706698A patent/ZA200706698B/xx unknown
- 2007-09-25 IL IL186267A patent/IL186267A0/en unknown
-
2010
- 2010-03-19 US US12/727,933 patent/US20100184729A1/en not_active Abandoned
- 2010-04-21 CL CL2010000395A patent/CL2010000395A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534552A5 (https=) | ||
| JP2009543842A (ja) | 心臓血管分野における直接トロンビン阻害薬のための新規適応 | |
| US20100184729A1 (en) | New Pharmaceutical Compositions for Treatment of Thrombosis | |
| CN100377742C (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 | |
| US20250099466A1 (en) | Milvexian for prevention and treatment of thromboembolic disorders | |
| EP1845961B1 (en) | Treatment of thromboembolic disorders with rivaroxaban | |
| US20080015176A1 (en) | New Paediatric Indications for Direct Thrombin Inhibitors | |
| JP2009543844A5 (https=) | ||
| JP4874482B2 (ja) | アスピリンを含有する医薬組成物 | |
| AU2010277725B2 (en) | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | |
| JP2008543853A (ja) | プラスグレルのための薬剤投与計画 | |
| US9393228B2 (en) | Combination of a slow sodium current blocker and a sinus If current inhibitor, and the pharmaceutical compositions containing said combination | |
| CN101489549A (zh) | 直接凝血酶抑制剂在心血管领域的新的适应症 | |
| ES2904256T3 (es) | Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos | |
| KR100782246B1 (ko) | 항혈전제와 항혈소판 응집제의 조합체 | |
| Cheng | Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention | |
| Weitz | Noncardiac surgery in the elderly patient with cardiovascular disease | |
| HK40073112A (en) | Methods of treating, reducing the incidence of, and/or preventing ischemic events | |
| HK1133402A (en) | New indications for direct thrombin inhibitors in the cardiovascular field | |
| HK1119932A (en) | Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis | |
| JP2007238609A (ja) | 糖尿病患者における虚血性疾患の予防のための医薬 | |
| CN107635556A (zh) | TAFIa抑制剂与纤溶酶原激活剂的联合 | |
| HK1144255A (en) | Oxazolidinone for the treatment and prophylaxis of pulmonary hypertension |